Disc Medicine (IRON) is down -14.3%, or -$12.92 to $77.52.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine’s Promising Position in Anemia Treatment Boosts Buy Rating Amidst Competitor Setback
- Disc Medicine Advances Bitopertin in FDA Pilot Program
- Evan Seigerman Recommends Buy Rating for Disc Medicine Due to Promising Phase 2 Data and Potential Stock Appreciation
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/8/2025, According to Top Analysts
- Disc Medicine’s Promising Pipeline and Strategic Expansion Drive Buy Rating